Auro Laboratories Limited
Fundamental Score
Auro Laboratories Limited Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of AUROLAB across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Robust Profit Growth (100.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (185.16%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Balanced Promoter Holding (52.18%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
7 factors identified
Premium Valuation Risk (P/E: 71.08x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Elevated Debt Levels (D/E: 1.01)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability and cash flow generation.
Limited Institutional Interest (FII+DII: 0.01%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Auro Laboratories Limited
About AUROLAB
Business Overview
Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. It offers antihistamine; muscle relaxant; diuretic; iron deficiency; anti-diabetic, including Metformin HCL; anti-fungal, ulcer, malaria, and inflammatory; iodine supplement; analgesics; antacids; potassium and sodium iodide; and microcrystalline cellulose. The company also provides specialty chemicals comprising guanidine nitrate; dimethyl amine HCl; 2-ethoxy benzoic acid; and 3,4,5 - trimethoxy benzoic acid. In addition, it offers intermediates consisting of glibenclamde sulphonamide for use in API glibenclamide; cis-bramo benzoate and cls-tosylate that are used in API Ketoconazol; 3,4,5 - trimethoxy benzoic acid; 2-ethoxy benzoic acid for use in API sildenafil citrate; and 5-bromo phthalide that is used in API citalopram. It also exports products to Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain, and the United Kingdom. The company was incorporated in 1989 and is based in Mumbai, India.
Company Details
Key Leadership
AUROLAB Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Auro Laboratories Limited (AUROLAB)?
As of 29 Jan 2026, 10:38 am IST, Auro Laboratories Limited (AUROLAB) is currently trading at ₹232.20. The stock has a market capitalization of ₹156.37 (Cr).
Is AUROLAB share price Overvalued or Undervalued?
AUROLAB is currently trading at a P/E ratio of 71.08x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Auro Laboratories Limited share price?
Key factors influencing AUROLAB's price include its quarterly earnings growth (Sales Growth: 185.16%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Auro Laboratories Limited a good stock for long-term investment?
Auro Laboratories Limited shows a 5-year Profit Growth of N/A% and an ROE of N/A%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.01 before investing.
How does Auro Laboratories Limited compare with its industry peers?
Auro Laboratories Limited competes with major peers in the Pharmaceuticals. Investors should compare AUROLAB's P/E of 71.08x and ROE of N/A% against the industry averages to determine its competitive standing.
What is the P/E ratio of AUROLAB and what does it mean?
AUROLAB has a P/E ratio of 71.08x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹71 for every ₹1 of annual earnings.
How is AUROLAB performing according to Bull Run's analysis?
AUROLAB has a Bull Run fundamental score of 24.5/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does AUROLAB belong to?
AUROLAB operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Auro Laboratories Limited.
What is Return on Equity (ROE) and why is it important for AUROLAB?
AUROLAB has an ROE of N/A%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Auro Laboratories Limited generates profits from shareholders' equity.
How is AUROLAB's debt-to-equity ratio and what does it indicate?
AUROLAB has a debt-to-equity ratio of 1.01, which indicates high leverage that increases financial risk. A ratio below 1.0 generally indicates conservative financing.
What is AUROLAB's dividend yield and is it a good dividend stock?
AUROLAB offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has AUROLAB grown over the past 5 years?
AUROLAB has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in AUROLAB and why does it matter?
Promoters hold 52.18% of AUROLAB shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is AUROLAB's market capitalization category?
AUROLAB has a market capitalization of ₹156 crores, placing it in the Small-cap category.
How volatile is AUROLAB stock?
AUROLAB has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for AUROLAB?
AUROLAB has a 52-week high of ₹N/A and low of ₹N/A.
What is AUROLAB's operating profit margin trend?
AUROLAB has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is AUROLAB's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 185.16% and YoY Profit Growth of 100.00%.
What is the institutional holding pattern in AUROLAB?
AUROLAB has FII holding of 0.00% and DII holding of 0.01%. Significant institutional holding often suggests professional confidence in the stock.